XML 25 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities    
Net loss $ (6,795,461) $ (9,735,258)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 1,244,121 1,888,944
Amortization of held-to-maturity securities, net (53,032) 33,790
Gain on investment in Alphazyme (1,017,592) 0
Foreign currency exchange loss 38,418 49,918
Changes in operating assets and liabilities:    
Operating lease assets and liabilities, net (4,510) 0
Interest receivable 48,202 36,090
Accounts receivable (141,332) (83,265)
Prepaid expenses and other current assets 64,902 (13,925)
Accounts payable (651,168) (248,128)
Accrued expenses 444,269 245,521
Deferred license revenue (352,942) (147,058)
Deferred research and development obligations 449,370 (110,404)
Net cash used in operating activities (6,726,755) (8,083,775)
Cash flows from investing activities    
Purchases of held-to-maturity investment securities (2,995,988) (9,869,280)
Proceeds from maturities of investment securities 9,148,000 7,500,000
Proceeds from the sale of investment in Alphazyme 1,297,884 0
Net cash provided by (used in) investing activities 7,449,896 (2,369,280)
Cash flows from financing activities    
Proceeds from exercise of options 0 543,591
Net cash provided by financing activities 0 543,591
Effect of exchange rate changes on cash (2,385) (44,744)
Net decrease in cash and cash equivalents 720,756 (9,954,208)
Cash and cash equivalents at beginning of period 5,794,272 15,748,480
Cash and cash equivalents at end of period 6,515,028 5,794,272
Supplemental cash flow information    
Vesting of restricted stock units 342,186 0
Right-of-use asset obtained in exchange for lease obligations $ 156,983 $ 0